Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Randomized, Placebo-Controlled, Single Ascending Dose-Escalation Study to Investigate ... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A Phase 1/2, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Assess the Safet... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'Immunogenicity of Recombinant Zoster Vaccine in Long-term Solid Organ Transplant Recipients'. The... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'Phase 3 Study of the Efficacy and Safety of ION582 in Children and Adults with Angelman Syndrome'... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Open-Label, Multicenter, Extension Study of Acoramidis in Patients with Newly Diagnose... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'Healthy longevity with rapamycin (LONGER)'. The following are the other relevant details related ... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcom... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'Efficacy and safety of LUCONAC ® External Solution for the treatment of Onychomycosis in anopen l... Read More
Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A multicenter, randomized, participant- and investigator - blinded, placebo-controlled, phase 2a ... Read More